SYMBYX Scientific Advisor and Co-Founder, Dr Ann Liebert, presented the results of the recent ground-breaking Parkinson's trial in Adelaide (which used the PDCare Laser by SYMBYX) at last week's Photobiomodulation 2021 Conference held jointly by WALT (the World Association for Photobiomodulation Therapy) and NAALT (the North American Association for Photobiomodulation Therapy).
The 2021 conference was held in Washington DC with Dr Liebert presenting her key note speech via video. These results were featured in a recent article in The Australian newspaper, in a Channel 9 TV news segment (and subsequently published in BMC Neurology Journal in July 2021).
The key takeaways of Ann's presentation (summarised for simplicity) were as follows:
1. The majority of Parkinson's light therapy Adelaide trial participants showed symptom improvements.
2. Positive changes were recorded in (a majority of) participants' cognition, gross and fine motor skills, sleep quality and increased sense of smell (even after several years of not smelling much).
3. Evidence is increasing behind the Gut-Brain connection involvement in additional neurological conditions such as Depression and Austism Spectrum Disorder.
4. After treatment directed towards the gut microbiome (using the SYMBYX PDCare Laser), the balance of gut bacteria changed in a positive way. Of course, Ann duly noted, with the microbiome, balance and bacterial diversity is important.
5. Light therapy successfully changed the microbiome in all trial participants after 12 weeks.
6. Trial participants increased bacteria generally associated with good health, eg, Bacteroides, Succinispira & Alistipes and decreased bacteria generally associated with ill health, eg, Streptococcus & Dorea.
7. There is still so much to lean about the microbiome.
Thanks Ann for an informative presentation.
Please contact our at info@symbyxbiome.com if you have any questions or would like to speak to one of our worldwide complimentary clinical support team members.
